Journal article
Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura
Curēus (Palo Alto, CA), v 12(5), 8156
16 May 2020
PMID: 32550073
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Valacyclovir is a well-tolerated antiviral drug. Thrombotic thrombocytopenic purpura is a rare adverse effect of valacyclovir therapy. Mostly, it has been reported in clinical trials and case reports in patients with high dose or low dose therapy in immunocompromised patients. Herein we write a case report of the immunocompetent patient, who was taking very low dose valacyclovir therapy for his recurrent genital herpes. This case emphasizes the role of low dose (1000 mg/day) valacyclovir therapy causing thrombotic thrombocytopenic purpura in an immunocompetent patient with no other explainable trigger.
Metrics
11 Record Views
Details
- Title
- Valacyclovir-Induced Thrombotic Thrombocytopenic Purpura
- Creators
- Sumera Bukhari - Seton Hall UniversityHafiz M Aslam - St. Francis Medical CenterTalha A Awwal - St Francis Medical CenterDonald Christmas - Cambridge Health AllianceSara L Wallach - Seton Hall University
- Publication Details
- Curēus (Palo Alto, CA), v 12(5), 8156
- Publisher
- Cureus
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- General Internal Medicine
- Web of Science ID
- WOS:000533197800009
- Other Identifier
- 991021962195304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Hematology